Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (321)	1/13/1999 10:38:00 PM
From: wolfdog2	Read Replies (1) \| Respond to of 712

George, Eisinger's comments are inane. Sales of a newly launched drug up to $700,000 per week, and he calls that a severely disappointing launch? Gimme a break. The problem lies not in the launch, but in the too high expectations of Wall St and sheep journalists who spout off to much.

To: aknahow who wrote (321)	1/14/1999 7:27:00 PM
From: Robert Mayo	Respond to of 712

Here's another spin on the story from Dow Jones: Dow Jones Newswires -- January 14, 1999 Dow Jones Newswires Cor Therapeutics CEO Says Integrilin Sales Progressing By MELANIE TROTTMAN Dow Jones Newswires "SAN FRANCISCO -- Sales of the drug Integrilin, which was launched last year, are progressing well, President and Chief Executive Vaughn Kailian said, although some on Wall Street have said the drug's launch has been slow. "Kailian thinks sales of the drug, which blocks blood-clot formation, could top $300 million annually if the company develops the market properly. "It's a very extensive education process," Kailian told Dow Jones at the Hambrecht & Quist Healthcare Conference here Thursday. He said he is "comfortable" with the 1998 sales estimates of about $10 million and with estimates of $50 million to $60 million in 1999. "Integrilin, along with Merck & Co.'s (MRK) Aggrastat and Eli Lilly & Co.'s (LLY) ReoPro, is part of a class of drugs that inhibit the formation of life-threatening blood clots in coronary patients. Like Integrilin, Aggrastat was approved last year, but ReoPro has been on the market since 1995. "Cor's advantage over the two competing drugs, Kailian said, is that Integrilin was approved for the largest number of uses in its class. It's also much less expensive than ReoPro, which costs about $1,350 a day, compared with Integrilin's daily price tag of $425, Kailian said. "The product is co-marketed through a partnership with Schering-Plough Corp. (SGP) and has made its way into 1,000 U.S. hospitals, he told Dow Jones. "He also said the 10-year-old company, based in San Francisco, has cash of more than $70 million and expects to reach profitability in the year 2001. "Cor Therapeutics' Chief Executive Kailian said Integrilin is also being studied for the treatment of additional indications, including heart attacks and strokes. "Outside of Integrilin, the company is conducting Phase II clinical trials of a once-a-day platelet blocker to be used for the prevention of heart attack and stroke. "Our data so far looks very good," Kailian said. "We think we're going to have the first once-a-day product" for this indication, he said. The trial will be completed in the first half of this year, with a second Phase II trial slated to begin in the second half of the year. "Cor doesn't have a marketing partner for the antiplatelet agent yet, but, he said, "there are interested parties." "In preclinical stages, Cor is conducting a small-molecule program expected to enter into clinical trials next year for use in the areas of oncology and angiogenesis." ##### ##### Bob

To: aknahow who wrote (321)	1/19/1999 10:04:00 PM
From: LLCF	Read Replies (1) \| Respond to of 712

<BTW don't get upset with the Eisinger comments. This is the sort of stuff I like to see and I hope management pays attention to. > Yea, folks... don't get all pissed off at these people, this is the guy on CNBC whos such a nut. This is their whole "schtick"... Gonzo business Journalism thats all. Doesn't mean you can't get something out of it. Don't shoot the mail man... when the funds start buying the small bio's these guys will be right there saying how the AMGN's of the world are Dinosaurs and the little guys are rocket fuel! DAK